Insider buying last 90 days
No open-market insider purchases were filed for SOLV in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SOLV insider filing, plotted on the chart in Gekko.Open SOLV in Gekko
NYSE: SOLV
Solventum (SOLV) Stock Analysis & Forecast
Sep 28 close
$89.54+0.04 (0.0%)
Gekko Brief
AI summaryThis week's attention on Solventum centers on a technical setup rather than fresh corporate news, with commentary pointing to a tight breakout pattern as the stock consolidates after a strong run and shows high technical and setup quality ratings. A separate balance sheet summary covering 2022 to 2025 figures added no new operational detail.
Solventum closes at $89.54, above both its 50-day average of $87.32 and its 200-day average of $77.83, with the shorter average sitting above the longer one, a configuration consistent with an established uptrend. The GekkoIndex reads 54.4, placing it in the Neutral zone, down 1.9 over five days. Against a Gekko Fair Value of $107.05, the current price sits 16.4% below that level.
The next earnings report is scheduled for 5 November 2026 after the close, 37 days away and outside a typical 20-trading-day holding window; the prior quarter beat estimates with EPS of $1.48 versus $1.34 expected and produced a 5.3% reaction, part of a run of 7 beats in the last 8 quarters. No insider, Congress or unusual options activity appears in the current windows, leaving smart-money positioning without a signal. Analyst coverage from 10 firms shows 7 buy and 3 hold ratings, with a consensus target of $93.92.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Solventum price vs fair value
Close $89.54200-day averageGekko Fair Value $107.05
Solventum quick facts
- Market cap
- $15.51B
- P/E ratio
- 10.8
- Forward P/E
- 13.1
- EPS, TTM
- $8.20
- Revenue, TTM
- $8.31B
- Profit margin
- 17.3%
- Dividend yield
- —
- Beta
- 0.69
- Volume
- 649,134 avg 885,242
- 1-year return
- +27.1%
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±5.9%
- 50-day average
- $87.32
- 200-day average
- $77.83
- Next earnings
- Nov 5 after close
- Shares outstanding
- 170.2M
Solventum swing-trade checklist
Solventum scores 3 supportive, 1 mixed and 0 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $89.54 is above the 50-day ($87.32) and 200-day ($77.83) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
54.4, Neutral
Reading 54.4 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
16.4% below
Price is 16.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Solventum stock chart and price history
Solventum closed at $89.54 on Sep 28, 2026, +27.1% over the past year, inside a 52-week range of $62.38 to $94.16.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −1.5%
- 3 months
- +14.4%
- 6 months
- +42.7%
- 1 year
- +27.1%
The full SOLV chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SOLV in Gekko
Follow Solventum through every session
Put SOLV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SOLV in GekkoFree for 7 days. No credit card required.
About Solventum
Solventum works in healthcare, developing, making and selling a range of products and services aimed at meeting needs across the industry, from clinical settings to individual patients. It covers ground spanning surgical and wound care supplies through to dental products and digital health software, giving it a footprint across several distinct areas of medical and clinical support.
The company organizes its operations into four segments. Medsurg covers wound care products, I.V. site tools, sterilization systems, temperature management devices, surgical instruments, stethoscopes and electrodes. Dental Solutions supplies orthodontic and dental items including brackets, clear aligners, filling materials and bonding agents. Health Information Systems focuses on software such as physician documentation tools, billing and coding automation, classification systems, voice recognition and data visualization. Purification and Filtration provides filters, purifiers, cartridges and membranes used in purification processes.
Solventum was established in 2023 and is headquartered in Saint Paul, Minnesota. Its shares are listed on the NYSE under the ticker SOLV.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- solventum.com
Solventum GekkoIndex: the smart money zone
Solventum’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.4, in the Neutral zone, down 1.9 points over five sessions.
54.4Neutral
Down 1.9 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 41 | −0.7% | +2.1% | ||
| Accumulation | 195 | +0.4% | +0.2% | ||
| Neutral (current zone) | 338 | +0.4% | +2.4% | ||
| Distribution | 48 | +0.3% | −0.5% | ||
| Selling | 1 | Too few readings yet | |||
Average SOLV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the SOLV price, zone by zone.Track SOLV in Gekko
Is Solventum stock overvalued? Gekko Fair Value
Solventum trades 16.4% below Gekko Fair Value of $107.05, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Solventum shares are worth, recalculated every trading day.
$107.05
Gekko Fair Value, Sep 26, 2026
16.4% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open SOLV in Gekko
Solventum insider and Congress trading
No open-market insider purchases were filed for Solventum, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SOLV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SOLV, plotted on the chart in Gekko.Open SOLV in Gekko
Buybacks
Solventum has been buying back its own shares.
- Latest authorization
- $1.00B, Dec 16, 2025
- Bought back, quarter ended Jun 30, 2026
- $288.0M
- As a share of market cap
- 1.86%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold SOLV.
0added0opened2trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Solventum earnings: next date and track record
Solventum reports on Nov 5, 2026, after the close (37 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 37 days away
- EPS estimate
- $1.35
- Revenue estimate
- $1.94B
7 of 8reports beat the EPS estimate
±4.5%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, May 5, 2026 AI summary
- What they said
- Solventum Q1 FY2026 results exceeded plan on both organic sales growth and EPS. All segments showed solid performance driven by commercial execution and new product launches, with better-than-expected margins from positive volume/mix and savings initiatives. The company is progressing on ERP cutovers, 3M separation, and its $500M Transform for the Future savings program. Portfolio optimization continues with the P&F business sale and Acera acquisition completed.
- Guidance
- Management reaffirmed 2026 full-year guidance, citing Q1 momentum as indicative of on-track delivery. Nearly 20 new products expected over the next two years. Transform for the Future program savings expected to accelerate meaningfully in 2027 and beyond.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 5, 2026 | $1.48 est $1.34 | $2.01B est $1.97B | +5.3% |
| Feb 26, 2026 | $1.57 est $1.50 | $2.00B est $1.96B | −1.2% |
| Nov 6, 2025 | $1.50 est $1.43 | $2.10B est $2.06B | +5.7% |
| Aug 7, 2025 | $1.69 est $1.45 | $2.16B est $2.12B | +1.1% |
| May 8, 2025 | $1.34 est $1.21 | $2.07B est $2.02B | +7.2% |
| Feb 27, 2025 | $1.41 est $1.50 | $2.07B est $2.05B | −5.1% |
| Nov 7, 2024 | $1.64 est $1.54 | $2.08B est $2.06B | −2.3% |
| Aug 8, 2024 | $1.56 est $1.51 | $2.08B est $2.05B | +8.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Solventum stock forecast and analyst price targets
Analysts’ average 12-month price target for Solventum is $93.92, +4.9% from the last close, from 10 firms rating the stock in the last 90 days.
$93.92consensus 12-month target, +4.9% from the last close
Now $89.54Avg $93.92
Low $84High $113
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | Stifel Nicolaus | $100 | +11.7% |
| Sep 15 | Piper Sandler | $105 | +17.3% |
| Sep 14 | BTIG | $95 | +6.1% |
| Aug 25 | BTIG | $95 | +6.1% |
| Aug 20 | UBS | $101 | +12.8% |
+2.4%average 20-day move after past Neutral readings
±2.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Solventum market cap and key statistics
Solventum’s market cap is $15.51B, with a P/E ratio of 10.8 and revenue of $8.31B over the last twelve months.
Valuation
- Market cap
- $15.51B
- P/E ratio
- 10.8
- Forward P/E
- 13.1
- EPS, TTM
- $8.20
- Gekko Fair Value
- $107.05
Trading
- Volume
- 649,134
- Avg volume, 20 days
- 885,242
- 52-week high
- $94.16
- 52-week low
- $62.38
- Shares outstanding
- 170.2M
Financials
- Revenue, TTM
- $8.31B
- Profit margin
- 17.3%
- Return on equity
- 34%
- Quarterly earnings growth, YoY
- +3.9%
Risk and income
- Beta
- 0.69
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±5.9%
Solventum stock news this week
2 headlines about Solventum from the past week, newest first, each linking to the publisher.
- Solventum (NYSE:SOLV) Forms Tight Breakout Setup as Technical Strength BuildsChartMill, Sep 23
- Solventum Corp (KB7.MU) balance sheet – Yahoo FinanceYahoo Finance Singapore, Sep 22
Solventum peers
Solventum’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Accumulation | 3.9% below |
| GHGuardant Health | Neutral | 0.5% above |
| EHCEncompass Health | Neutral | 7.6% above |
| DVADaVita | Accumulation | 15.9% below |
| BTSGBrightSpring Health Services | Accumulation | 7.4% below |
| ENSGEnsign | Neutral | 11.2% above |
A peer links to its own page where one exists.
Solventum stock FAQ
What is Solventum’s market cap?
Solventum’s market cap is $15.51B at the Sep 28, 2026 close of $89.54, with 170.2M shares outstanding. The shares trade on a P/E ratio of 10.8.
What is the Solventum stock forecast?
The consensus analyst 12-month price target for Solventum is $93.92, +4.9% from the last close. Of the 10 firms that rated the stock in the last 90 days, 7 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Solventum stock overvalued or undervalued?
On Gekko’s estimate Solventum is undervalued: the Sep 28, 2026 close of $89.54 is 16.4% below Gekko Fair Value of $107.05. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Solventum report earnings next?
Solventum is expected to report on Nov 5, 2026, after the market closes (37 days away). Analysts expect earnings of $1.35 per share on revenue of $1.94B. Solventum beat the earnings estimate in 7 of its last 8 reports, moving 4.5% on average across the report.
What is Solventum’s 52-week high and low?
Solventum’s 52-week high is $94.16 and its 52-week low is $62.38; it closed at $89.54 on Sep 28, 2026, +27.1% over the past year. Over the last five years the shares peaked at $96.05 on Mar 26, 2024.
Is Solventum stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 4 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Solventum the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.